Anti-pd-1 antibodies and uses thereof
By developing monoclonal antibodies or their antigen-binding fragments that specifically bind to human PD-1, the technical difficulties of neutralizing PD-1 negative signals and stimulating immune responses have been solved, achieving safe and effective therapeutic effects in humans.
CN113811329BActive Publication Date: 2025-10-14TCRCURE BIOPHARMA CORP +1
40 Cites 0 Cited by
Patent Information
- Application Number
- CN202080029657.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-19
- Filing Date
- 2020-04-17
- Publication Date
- 2025-10-14
- Estimated Expiration
- 2040-04-17
AI Technical Summary
Technical Problem
The existing technology lacks effective methods to neutralize/block PD-1 negative signals and stimulate immune responses, especially in the treatment of cancer and other diseases.
Method used
We have developed monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human PD-1, and have provided humanized antibodies to improve safety and efficacy by redesigning mouse antibodies to reduce immunogenicity in humans.
Benefits of technology
These antibodies can effectively neutralize PD-1 signals, stimulate immune responses, and are used to treat cancer and other diseases, improving therapeutic efficacy and reducing the risk of immune responses.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1 / PD-L2. The present disclosure also relates to antibodies that are chimeric antibodies, humanized antibodies, bispecific antibodies, derivatized antibodies, single-chain antibodies, portions of fusion proteins, or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing the antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. The present disclosure also provides uses of these antibodies for enhancing T cell function and upregulating cell-mediated immune responses for the treatment and prevention of various diseases.
Need to check novelty before this filing date? Find Prior Art